StockNews.AI
AEHR
StockNews.AI
211 days

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aehr Test Systems

1. Faruqi & Faruqi is investigating claims against Aehr for false statements. 2. Aehr cut its 2024 revenue forecast to $65 million amid significant order delays. 3. On March 25, 2024, Aehr's stock fell 22.44% after poor revenue estimates. 4. The lawsuit stresses misleading claims about Aehr's customer order visibility. 5. Investors have until February 3, 2025, to seek lead plaintiff status.

6m saved
Insight
Article

FAQ

Why Very Bearish?

The sharp stock drop signals severe investor mistrust, resembling past cases of revenue miss.

How important is it?

The allegations and stock response highlight potential company mismanagement affecting investor confidence.

Why Short Term?

Immediate market reactions to earnings forecasts commonly impact stock prices significantly short-term.

Related Companies

AEHR
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aehr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aehr between January 9, 2024 and March 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aehr Test Systems, Inc. ("Aehr" or the "Company") (NASDAQ:AEHR) and reminds investors of the February 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) contrary to prior representations to investors, Aehr was continuing to experience substantial delays in customer orders; (2) the foregoing issue was likely to have a material negative impact on the Company's revenue growth; (3) accordingly, the Company's business and/or financial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.In October 2023, Aehr provided guidance for its fiscal full year 2024 financial results. Specifically, the Company stated that it expected "total revenue to be at least $100 million, representing growth of over 50% year over year[.]"On January 9, 2024, Aehr cut its 2024 revenue forecast from $100 million to $75-$85 million, citing "a delay in the timing of new orders from current and new customers that will most likely impact this fiscal year's revenue." However, the Company's Chief Executive Officer Defendant Gayn Erickson was quick to downplay the significance of the updated forecast on a related earnings call that same day, claiming that the Company "took a very conservative stance in hopes there's no way we'll miss it on the low end, but I can see scenarios where we could be higher than the [$75-$85 million] range" and advising investors and analysts that the Company had "very good visibility" into its customers' order patterns.Then, on March 25, 2024, Aehr announced preliminary fiscal Q3 2024 financial results. Among other things, the Company revealed that its Q3 revenue was estimated to be approximately $7.6 million, versus a consensus of $14.32 million, citing delays in wafer level burn-in system orders for semiconductor devices used in electric vehicles that have created a short-term gap in revenue and profitability. In addition, Aehr further cut its 2024 revenue forecast, stating that it now expected revenue of at least $65 million versus a consensus of $77.43 million.On this news, Aehr's stock price fell $3.29 per share, or 22.44%, to close at $11.37 per share on March 25, 2024.The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.Faruqi & Faruqi, LLP also encourages anyone with information regarding Aehr's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the Aehr class action, go to www.faruqilaw.com/AEHR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.SOURCE: Faruqi & Faruqi, LLP

Related News